Literature DB >> 2394835

Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.

G B Mills1, C May, M Hill, S Campbell, P Shaw, A Marks.   

Abstract

Human ovarian cancer, the leading cause of death from gynecologic malignancy, tends to remain localized to the peritoneal cavity until late in the disease. In established disease, ascitic fluid accumulates in the peritoneal cavity. We have previously demonstrated that this ascitic fluid is a potent source of in vitro mitogenic activity including at least one unique growth factor. We now report that the human ovarian adenocarcinoma line, HEY, can be induced to grow intraperitoneally in immunodeficient nude mice in the presence (23/28 mice), but not absence (0/21 mice) of ascitic fluid from ovarian cancer patients. Ascitic fluid from patients with benign disease did not have similar effects on intraperitoneal growth of HEY cells (1/15 mice). Once tumors were established by injections of exogenous ascitic fluid, they could progress in the absence of additional injections of ascitic fluid. The mice eventually developed ascitic fluid which contained potent growth factor activity, suggesting that the tumors eventually produced autologous growth factors. This nude mouse model provides a system to study the action of ovarian cancer growth factors on tumor growth in vivo and to evaluate preclinically, therapeutic approaches designed to counteract the activity of these growth factors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2394835      PMCID: PMC296802          DOI: 10.1172/JCI114784

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  10 in total

Review 1.  Common epithelial cancer of the ovary (2).

Authors:  G S Richardson; R E Scully; N Nikrui; J H Nelson
Journal:  N Engl J Med       Date:  1985-02-14       Impact factor: 91.245

2.  Characterization of binding of four monoclonal antibodies to the human ovarian adenocarcinoma cell line HEY.

Authors:  K Sheldon; A Marks; R Baumal
Journal:  Biochem Cell Biol       Date:  1987-05       Impact factor: 3.626

Review 3.  Autocrine growth factors and cancer.

Authors:  M B Sporn; A B Roberts
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

Review 4.  Common epithelial cancer of the ovary (2).

Authors:  G S Richardson; R E Scully; N Nikrui; J H Nelson
Journal:  N Engl J Med       Date:  1985-02-21       Impact factor: 91.245

Review 5.  The molecular genetics of cellular oncogenes.

Authors:  H E Varmus
Journal:  Annu Rev Genet       Date:  1984       Impact factor: 16.830

6.  Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies.

Authors:  P Shaw; R Buckman; J Law; R Baumal; A Marks
Journal:  Tumour Biol       Date:  1988

7.  Comparative properties of five human ovarian adenocarcinoma cell lines.

Authors:  R N Buick; R Pullano; J M Trent
Journal:  Cancer Res       Date:  1985-08       Impact factor: 12.701

8.  Monoclonal antibodies to an epithelial ovarian adenocarcinoma: distinctive reactivity with xenografts of the original tumor and a cultured cell line.

Authors:  R Baumal; J Law; R N Buick; H Kahn; H Yeger; K Sheldon; T Colgan; A Marks
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

9.  A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action.

Authors:  G B Mills; C May; M McGill; C M Roifman; A Mellors
Journal:  Cancer Res       Date:  1988-03-01       Impact factor: 12.701

10.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Authors:  M T Lotze; Y L Matory; S E Ettinghausen; A A Rayner; S O Sharrow; C A Seipp; M C Custer; S A Rosenberg
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

  10 in total
  41 in total

Review 1.  The human plasma lipidome.

Authors:  Oswald Quehenberger; Edward A Dennis
Journal:  N Engl J Med       Date:  2011-11-10       Impact factor: 91.245

2.  Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

Authors:  Tugan Bese; Merve Barbaros; Elif Baykara; Onur Guralp; Salih Cengiz; Fuat Demirkiran; Cevdet Sanioglu; Macit Arvas
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

3.  Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.

Authors:  Pradeep Chaluvally-Raghavan; Kang Jin Jeong; Sunila Pradeep; Andreia Machado Silva; Shuangxing Yu; Wenbin Liu; Tyler Moss; Cristian Rodriguez-Aguayo; Dong Zhang; Prahlad Ram; Jinsong Liu; Yiling Lu; Gabriel Lopez-Berestein; George A Calin; Anil K Sood; Gordon B Mills
Journal:  Cell Rep       Date:  2016-05-05       Impact factor: 9.423

4.  Role of malignant ascites on human mesothelial cells and their gene expression profiles.

Authors:  Isabelle Matte; Denis Lane; Dimcho Bachvarov; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2014-04-24       Impact factor: 4.430

5.  Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer.

Authors:  Vijayalakshmi N Ayyagari; Nancy A Johnston; Laurent Brard
Journal:  Anticancer Drugs       Date:  2016-07       Impact factor: 2.248

6.  Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.

Authors:  Lauren P Saunders; Amy Ouellette; Russ Bandle; William Chozen Chang; Hongwen Zhou; Raj N Misra; Enrique M De La Cruz; Demetrios T Braddock
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

7.  Phenotypic variations and differential migration of NIH:OVCAR-3 ovarian carcinoma cells isolated from athymic mice.

Authors:  A L Veatch; L F Carson; S Ramakrishnan
Journal:  Clin Exp Metastasis       Date:  1995-05       Impact factor: 5.150

8.  The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  J Ovarian Res       Date:  2010-01-18       Impact factor: 4.234

9.  Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.

Authors:  Shelley B Hooks; Phillip Callihan; Molly K Altman; Jillian H Hurst; Mourad W Ali; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-11-02       Impact factor: 27.401

10.  Growth stimulation of ovarian and extraovarian mesothelial cells by corpus luteum extract.

Authors:  S Setrakian; B Oliveros-Saunders; S V Nicosia
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-11       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.